Spark Therapeutics

Spark Therapeutics is a United States biotechnology company focused on gene therapies for serious inherited diseases. The company emerged from translational work at Children's Hospital of Philadelphia, particularly research led by ophthalmologist and gene-therapy scientist Katherine A. High. High, Jeffrey Marrazzo, and Steven Altschuler founded Spark in 2013 to move gene-therapy research toward commercial development, initially with a strong emphasis on hemophilia and other disorders for which conventional treatment options were limited. Spark became one of the most visible companies in the modern gene-therapy industry after developing voretigene neparvovec, marketed as Luxturna. The treatment uses an adeno-associated viral vector to deliver a functional copy of the RPE65 gene to the retina. The United States Food and Drug Administration approved Luxturna in December 2017 for eligible patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The approval was historically significant because it represented one of the first gene therapies approved in the United States for an inherited disease and one of the first treatments intended to address the underlying genetic cause of an inherited vision disorder rather than merely manage symptoms. The company also built a broader pipeline based on viral-vector gene transfer. Programs included treatments for hemophilia A and B, choroideremia, Pompe disease, and Batten disease. Its hemophilia B program, originally identified as SPK-9001 and later known as fidanacogene elaparvovec, was developed with Pfizer. The therapy is designed to deliver a functional Factor IX gene to the liver of patients with hemophilia B. The United States approved the product in 2024 under the name Beqvez, although commercialization and ownership arrangements are associated with Pfizer following the companies' collaboration. Spark became a public company in January 2015, raising approximately $161 million in an initial public offering and trading on Nasdaq under the symbol ONCE. Its public-market period ended after Roche agreed to acquire the company. Roche completed the transaction in December 2019 for approximately $4.3 billion, and Spark became a Roche subsidiary while continuing to operate with a degree of organizational independence. The acquisition gave Roche access to Spark's gene-therapy platform, clinical programs, manufacturing capabilities, and commercial experience with Luxturna. Following the acquisition, several senior figures associated with Spark's founding and early growth left the company. Katherine High departed in 2020, Joseph La Barge left in 2021, and co-founder and chief executive Jeffrey Marrazzo departed in 2022. Ron Philip was named Marrazzo's successor in February 2022 and has led the organization according to the cited reference material. Spark's identity remains closely associated with the development and delivery of genetic medicines, particularly treatments for rare diseases in which a single defective gene can be addressed through targeted gene replacement.

Spark Therapeutics was founded in 2013 by Katherine A. High, Jeffrey Marrazzo, and Steven Altschuler. Its origins lay in gene-therapy research at Children's Hospital of Philadelphia, where High had worked on approaches to treat hemophilia and other inherited disorders. The founders created Spark to translate this research into commercially viable medicines for patients with severe genetic diseases. The company initially pursued a platform strategy built around adeno-associated viral vectors. These vectors can be engineered to carry a working copy of a gene into selected cells, potentially addressing the biological cause of a disease rather than providing only repeated symptomatic treatment. Spark's programs covered inherited retinal disorders, hemophilia A and B, and several central nervous system and metabolic diseases. Spark's most important early achievement was the development of voretigene neparvovec. The product, marketed as Luxturna, delivers a functional RPE65 gene to retinal cells. In December 2017, the FDA approved Luxturna for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy who retain viable retinal cells. The authorization made Luxturna a landmark product in the United States gene-therapy market and established Spark as a leading commercial gene-therapy specialist. Spark entered the public markets in January 2015 through an initial public offering that raised approximately $161 million. Its shares traded on Nasdaq under the symbol ONCE. The company used its public-company resources to advance its clinical pipeline and expand capabilities in development, manufacturing, regulatory work, and commercialization. Roche agreed to acquire Spark in 2019, and the transaction was completed in December of that year for approximately $4.3 billion. Spark subsequently operated as a subsidiary of Roche while retaining its own organizational identity. The acquisition connected Spark's rare-disease and gene-therapy portfolio with Roche's global pharmaceutical infrastructure. The post-acquisition period included substantial senior-management turnover. High departed in February 2020, followed by chief business and legal officer Joseph La Barge in December 2021. Co-founder and chief executive Jeffrey Marrazzo left in April 2022. Ron Philip was identified as Marrazzo's successor in February 2022 and, according to the cited material, leads the organization. Spark's pipeline has also included fidanacogene elaparvovec, formerly known as SPK-9001. Developed with Pfizer, the therapy is designed to transfer a functional Factor IX gene into liver cells in people with hemophilia B. The FDA approved the treatment in 2024. Other programs described in reference material include SPK-8011 for hemophilia A, SPK-7001 for choroideremia, SPK-3006 for Pompe disease, and SPK-1001 for Batten disease. Together, these programs reflect Spark's historical strategy of applying gene replacement to rare diseases affecting the eye, blood-clotting system, nervous system, and metabolism.

• 2024

  Hemophilia B gene therapy approved

  [3]FDA approves gene therapy for adults with hemophilia Bfda.gov

  Fidanacogene elaparvovec, a Spark-originated program developed with Pfizer, receives FDA approval.

• 2019

  Roche acquisition announced and completed

  [1]Spark Therapeuticsen.wikipedia.org

  Roche acquires Spark in a transaction valued at approximately $4.3 billion, with Spark continuing as a subsidiary.

• 2017

  Luxturna receives FDA approval

  [2]FDA approves novel gene therapy to treat patients with rare form of inherited vision lossfda.gov

  The FDA approves voretigene neparvovec for eligible patients with biallelic RPE65 mutation-associated retinal dystrophy.

• 2015

  Initial public offering

  [1]Spark Therapeuticsen.wikipedia.org

  Spark becomes publicly traded on Nasdaq under the symbol ONCE and raises approximately $161 million in its IPO.

• 2013

  Spark Therapeutics is founded

  [1]Spark Therapeuticsen.wikipedia.org

  Katherine A. High, Jeffrey Marrazzo, and Steven Altschuler establish Spark to develop gene therapies emerging from research at Children's Hospital of Philadelphia.

A specialist gene-therapy developer focused on rare and debilitating inherited diseases, with expertise spanning viral-vector design, clinical development, manufacturing, and commercialization.

• Inherited retinal disease gene therapy · 2017

  Luxturna (voretigene neparvovec)

  Luxturna is an adeno-associated viral-vector gene therapy that delivers a functional copy of the RPE65 gene to retinal cells. It is intended for eligible patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The FDA approved it in December 2017, making it a landmark commercial treatment for an inherited genetic cause of vision loss.

• Hemophilia B gene therapy · 2024

  Fidanacogene elaparvovec (SPK-9001)

  Fidanacogene elaparvovec is an adeno-associated viral-vector therapy designed to deliver a functional Factor IX gene to liver cells in adults with hemophilia B. Spark developed the program in partnership with Pfizer. The therapy received FDA approval in 2024 and is marketed as Beqvez.

• Hemophilia A gene therapy

  SPK-8011 (dirloctogene samoparvovec)

  SPK-8011 is an investigational gene therapy designed to deliver a functional Factor VIII gene to patients with hemophilia A. Reference material describes immune responses in some participants at a high dose during phase 2 development, including one hospitalization, while Spark continued evaluating steroid management and later-stage testing.

• Choroideremia gene therapy

  SPK-7001

  SPK-7001 is an investigational gene-therapy program for choroideremia, an inherited disorder associated with progressive retinal degeneration and vision loss.

• Pompe disease gene therapy

  SPK-3006

  SPK-3006 is an investigational gene-therapy program for Pompe disease, a genetic metabolic disorder in which the body cannot properly process glycogen.

• Batten disease gene therapy

  SPK-1001

  SPK-1001 is an investigational program for Batten disease, a group of inherited nervous-system disorders that can cause progressive neurological decline and premature death.

• 2019

  Roche acquisitionM&A

  Background

  Spark had established a commercial gene-therapy platform through Luxturna and maintained a pipeline targeting rare inherited diseases.

  Action taken

  Roche acquired Spark Therapeutics for approximately $4.3 billion.

  Aftermath

  Spark became a Roche subsidiary and continued operating under its own identity, with access to Roche's broader pharmaceutical resources.

  Acquisition value. $4.3 billion (2019 acquisition, completed December 2019)

  Source

• 2015

  Public-market financing to expand gene-therapy developmentStrategy

  Background

  Spark was advancing Luxturna and a wider pipeline of gene therapies for rare inherited diseases and required capital for clinical development and corporate infrastructure.

  Action taken

  The company completed an initial public offering on Nasdaq under the ticker ONCE, raising approximately $161 million.

  Aftermath

  The IPO provided resources for Spark's development programs and supported its transition from a research-focused venture into a public biotechnology company.

  IPO proceeds. $161 million raised (January 2015)

  Source

• Unconfirmed

  Roche completes acquisition of Spark Therapeutics[5]Roche 完成对 Spark Therapeutics 的收购medcitynews.com

  Reported: 2019-12-17

  Roche completed its acquisition of Spark Therapeutics after Spark accepted a tender offer for all outstanding common shares at $114.50 per share. Spark became a wholly owned subsidiary of Roche, and its shares would no longer be traded on Nasdaq.

• 2019-12-16

  Regulators close investigation into Roche's acquisition of Spark Therapeutics[5]Roche 完成对 Spark Therapeutics 的收购medcitynews.com

  Reported: 2019-12-17

  The U.S. Federal Trade Commission and the U.K. Competition and Markets Authority closed their 10-month investigation into Roche's acquisition of Spark Therapeutics and whether it would harm competition in the hemophilia A treatment space.

• 2019-12-16

  UK regulator clears Roche's acquisition of Spark Therapeutics[6]英国监管机构放行罗氏收购Spark Therapeuticsfinance.sina.com.cn

  Reported: 2019-12-16

  The UK Competition and Markets Authority cleared Roche's $4.3 billion acquisition of Spark Therapeutics. The deal still required US regulatory approval.

• 2019-12-16

  Regulators approve Roche-Spark acquisition[7]监管机构批准 Roche 收购 Sparkhealio.com

  Reported: 2019-12-17

  The U.K. Competition and Markets Authority and the U.S. Federal Trade Commission approved the Roche-Spark acquisition on Monday, clearing the remaining regulatory hurdles described in the report.

  Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.

1. 1Spark Therapeuticsen.wikipedia.org
2. 2FDA approves novel gene therapy to treat patients with rare form of inherited vision lossfda.gov
3. 3FDA approves gene therapy for adults with hemophilia Bfda.gov
4. 4Spark Therapeutics official websitesparktx.com
5. 5Roche 完成对 Spark Therapeutics 的收购medcitynews.com
6. 6英国监管机构放行罗氏收购Spark Therapeuticsfinance.sina.com.cn
7. 7监管机构批准 Roche 收购 Sparkhealio.com
8. 8罗氏43亿美元基因治疗收购案获英国放行 美国仍在“拖后腿”tech.sina.com.cn
9. 9Philly-based Spark Therapeutics acquired by Roche in $4.3 billion dealphillyvoice.com
10. 10Roche acquires Spark Therapeutics to strengthen presence in gene therapybiospectrumindia.com